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Schistosomiasis affects millions of people, yet treatment options are limited. The antimalar-
ial Synriam (piperaquine 150mg/arterolane750 mg) and the anthelminthicmoxidectin
revealed promising antischistosomal properties in preclinical or clinical studies.
Methodology
We conducted two single-blind, randomized exploratory Phase 2 trials in Schistosomaman-
soni and S. haematobium-infected adolescents in northernand central Côte d’Ivoire. Our
primaryendpoints were cure rates (CRs) and egg reduction rates (ERRs) based on geomet-
ric mean and safety. Each subject was asked to provide two stool samples (S.mansoni trial)
for Kato-Katz analysis or three urine samples (S. haematobium trial) for urine filtration and
one finger prick for malaria screening at baseline and follow-up. Participants were randomly
assigned to either moxidectin, Synriam, Synriamplus praziquantel or praziquantel.
Principal Findings
128 adolescents (age: 12–17 years) were included in each study. Against S. haematobium
moxidectin and Synriam revealed low efficacy. On the other hand, Synriam plus praziquan-
tel and praziquantel yielded CRs of 60.0% and 38.5% and ERRs of 96.0% and 93.5%,
respectively. CRs observed in the treatment of S.mansoniwere 13.0%, 6.7%, 27.0%, and
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27.6% for moxidectin, Synriam, Synriamplus praziquantel and praziquantel, respectively.
ERRs ranged from 64.9% (Synriam) to 87.5% (praziquantel).
Conclusion/Significance
Synriamand moxidectin show low efficacy against S. haematobium, hence an ancillary
benefit is not expected when these drugs are used for treating onchocerciasis and malaria
in co-endemic settings. Further studies are needed to corroborate our findings that moxi-
dectin and Synriam show moderate ERRs against S.mansoni.
Author Summary
Schistosomiasis is a parasitic infection that affects millions of people all over the world and
it is due to schistosomes, helminths (worms) that infect the intestine and the urinary blad-
der. Treatment options are limited, with praziquantel being the only used drug. The anti-
malarial Synriam and the anthelminthic moxidectin revealed good action against this
worm in previous studies. We conducted two studies in Schistosoma mansoni and S. hae-
matobium-infected adolescents in Côte d’Ivoire. Subjects positive for the infectionwere
allocated by chance to the four groups of treatment (moxidectin, Synriam, Synriam plus
praziquantel or praziquantel); participants did not know which drug they took. Our aim
was to calculate how many participants were negative after the treatment and how did the
intensity of infection change before and after treatment. Each subject provided stools and
urines for examination. 128 adolescents were included in each study. Moxidectin and Syn-
riam did not work well against S. haematobium. Against S.mansoni, only a small part of
the participants were negative after treatment in all treatment groups, but the intensity of
infections were reduced. Further studies are needed to better understand this result.
Introduction
Schistosomiasis caused by the three main species Schistosoma haematobium, S. japonicum and
S.mansoni is a disease known since ancient times. An estimated 230 million people are infected
and the disease causes a burden of 3.0 million disability-adjusted life years lost [1, 2]. Despite
the enormous public health problem with regard to symptomatology and morbidity, it is listed
among the so-called neglected tropical diseases (NTDs) [3]. The treatment of schistosomiasis
relies on one drug only, praziquantel, which is active against adult schistosomes, but has little
activity against juvenile worms [3]. The high drug pressure resulting from the widespread
administration of praziquantel in the framework of preventive chemotherapy programs could
lead to drug resistance [4]. However, at the moment there are no viable alternatives to prazi-
quantel [5]. Even so, drug discovery has languished, and no drug is currently undergoing clini-
cal testing [6]. Therefore, the discovery and development of new drugs for the treatment of
schistosomiasis is a high priority.
The antischistosomal activity of the artemisinins was describedmore than 30 years ago [7].
Subsequently, many studies have been conducted to elucidate the antischistosomal effect of the
artemisinins and synthetic peroxides [8, 9]. The 1,2,4-trioxolanes in particular, characterized
by improved pharmacokinetic parameters compared to the artemisinins [10], were the focus of
different in vitro and in vivo studies, which demonstrated efficacy not only against Schistosoma
spp. but also against Echinostoma caproni, Fasciola hepatica and Clonorchis sinensis [9, 11]. In
SynriamandMoxidectin for Schistosomiasis
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more detail, OZ78, OZ277 and OZ209 were first studied in S.mansoni and S. japonicum rodent
models more than a decade ago. A particularly high activity of the 1,2,4-trioxolanes was
observed against juvenile S.mansoni and S. japonicum infections in the mouse model and
against both juvenile and adult stages of the worms in the hamster model [11]. After licensing
OZ277 (arterolane maleate) in combination with piperaquine in 2011 (Synriam) [12–14] Mos-
sallam and colleagues studied the efficacy of OZ277 in combination with piperaquine in
rodents infected with S.mansoni, which confirmed the excellent activity of this trioxolane
derivative particularly against the worms’ juvenile stages [15].
Moxidectin is widely used in veterinarymedicine for heartworms [16]. Studies are ongoing
to develop moxidectin as potential alternative to ivermectin for the treatment of onchocerciasis
[17]. In the framework of this drug development program effects of moxidectin on concomi-
tant helminths were studied [18], revealing cure rates (CR) and egg reduction rates (ERR) of
64% and 66%, respectively in S.mansoni-infected patients [19].
We conducted two single-blinded, randomized exploratory Phase 2 trials in S. haematobium
and S.mansoni-infected adolescents to assess the efficacy of moxidectin and Synriam. One
group of children was treated with a combination of Synriam and praziquantel since this com-
bination might offer effects against pre-patent and patent infections. Finally, praziquantel
treated participants served as active control.
Methods
Ethics statement
Ethical clearance was obtained from the ethics committee of Northern and Central Switzerland
(EKNZ; reference no. 15/01) and from the Comité National d’Éthique et de la Recherche du
Ministère de la Santé et de l’Hygiène Publique (reference no. 026) in Côte d’Ivoire. The trial is
registered with Current Controlled Trials (ISRCTN 63657086). Participants aged 12–18 years
old were eligible for inclusion in the trial.Written informed consent was obtained before enrol-
ment by the children aged 18 years and by parents or legal guardians of the children below 18
years old. The latter assented orally.
Study setting and population
The single-blind, randomized, exploratory, four arm Phase 2 trials were conducted in May and
June 2015, in the health districts of Toumodi (Moronou village (geographical co-ordinates 06°
19’0” N latitude, 04°58’0”W longitude), endemic for S. haematobium) and Man (villages of
Bigouin (7°24’01” N, 7°33’11”W) and Biakalé (7°27’07” N, 7°41’32”), endemic for S.mansoni)
of Côte d’Ivoire. In all locations, village based recruitment was implemented.
Randomization and drugs
We used a computer-generated block randomization code stratified by baseline infection inten-
sities (block size of 8) provided by an independent statistician. Enrolled subjects were randomly
allocated to the four treatment arms i) single dose of moxidectin liquid formulation 8 ml (8
mg), ii) Synriam (150 mg arterolane plus 750 piperaquine): three doses administered for three
consecutive days, iii) Praziquantel 40 mg/kg single dose plus Synriam (150 mg arterolane plus
750 piperaquine) three doses administered for three consecutive days, iv) Praziquantel 40 mg/
kg single dose. Since drug interactions were not yet studied, the combination treatment group
received praziquantel in the morning followed by Synriam in the late afternoon (and two addi-
tional Synriam courses over the next two days). Only the study investigator was aware of the
treatment assignments, while children and laboratory technicians were blinded.Moxidectin
SynriamandMoxidectin for Schistosomiasis
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was administered as oral suspension (Cydectin 0.1% Zoetis, Switzerland) mixed with equal
amounts of mint syrup (sweetener RK50 (E952 (SodiumCyclamate), E954 (SodiumSaccha-
rin); Peppermint Plus Aroma and Citrus Plus Aroma [Rohner Konzept, Switzerland]) to mask
the bitter taste of the drug. Praziquantel was administered based on subjects’ weight using 600
mg tablets (Cesol,Merck).
Study procedures
Community meetings were conducted to explain the purpose, procedures, potential risks and
benefits of the study. At baseline three urine samples (S. haematobium cohort) and two stool
samples (S.mansoni cohort) were collected from participants. Schistosome-positive adoles-
cents, who had provided 2 stool and 3 urine samples were eligible to participate in the trials.
One stool sample was collected from each participant in the S. haematobium trial and one
urine sample from each patient participating in the S.mansoni trial to evaluate co-infections.
The standard urine filtrationmethod (10 ml of urine) was used for appraisal of S. haemato-
bium infections [3, 20]. Microhematuria was assessed on one urine sample using Hemastix
(Siemens, Munich, Germany) dipsticks. The Kato-Katz technique was used for the quantitative
assessment of S.mansoni infections. Duplicate Kato-Katz was performed on each stool sample
using the 41.7 mg template according to the standardizedmethod [21]. All slides were double-
checked by a second laboratory technician; slides were considered negative only if no parasites
were detected by the two independentmicroscopists. Concomitant infections with soil-trans-
mitted helminth (STH) infections were recorded. In addition, we used the circulating cationic
antigen (CCA) tests (ICT diagnostics, Cape Town, South Africa) on one urine sample for S.
mansoni diagnosis. The POC-CCAcassette (batch 33112) was performed according to the
manufacturer’s instructions. The test results were scored as negative or positive, the latter strat-
ified into trace (very light color band), 1+, 2+ (light infection), and 3+ (heavy infection) accord-
ing to the visibility of the color reaction. On the day of treatment and physical examination,
participants provided one finger prick sample for malaria and hemoglobin testing. The hemo-
globin concentration was determined using a portable Hemocue 301 (HemoCue AB; Ängel-
holm, Sweden). Additionally, a rapid malaria diagnostic test (RDT) (ICT diagnostics) was
employed. Thick and thin blood smears were prepared on a microscope slide for subsequent
appraisal of malaria parasitemia. The medical history of participants was assessed with a stan-
dardized questionnaire, in addition to a clinical examination carried out by the study clinician.
Height was measured with a standard meter (to the nearest 1 cm) and weight with an accurate
electronic balance (to the nearest 0.1 kg). After treatment adverse events were monitored at 3,
24, 48 and 72 hours after each dose of treatment was administered. Participants were excluded
if they suffered from any systematic illness (e.g. clinical malaria).
At day 21 after the last treatment dose was provided we sampled again 3 urine and 2 stool
specimens for analysis of S. haematobium, S.mansoni and STH infections, together with a fin-
ger prick for the diagnosis of malaria infection. At the end of the study all participants positive
for S.mansoni, S. haematobium, and STH infections were treated with albendazole (400 mg)
and/or praziquantel (40 mg/kg) and artesunate and lumefantrine following national guidelines
for malaria treatment.
Sample size and statistical analysis
We aimed for 25 participants per treatment arm, a common sample size for exploratory Phase
2 trials [22]. Allowing for an attrition rate of up to 20%, it was planned to include 30 partici-
pants per treatment arm. For the estimation of the prevalence of S.mansoni and S. haemato-
bium infection in these settings we based our calculation on a previously reported prevalence
SynriamandMoxidectin for Schistosomiasis
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of 60–70% at nearby sites [23, 24]. However, we used a conservative estimate of 60% for our
sample size determination and hence we planned to screen 200 subjects in each study cohort to
detect at least 120 eligible participants infectedwith S.mansoni/S. haematobium.
Results were double entered in a database (Excel 2010), cross-checked and analyzed with
Stata 12.0 (Lakeway Drive College station, TX, Unites States of America). An available case
analysis was performed, which included all children with primary outcome data. The intensity
of S.mansoni infection (number of eggs per gram (epg) of feces) was assessed by adding up the
egg counts from the quadruplicate Kato-Katz thick smears (from baseline and follow-up sepa-
rately) and multiplying this number by a factor of six [25]. The intensity of infection for S. hae-
matobium was assessed by calculating the average of the egg counts from the triplicate urine
filtration. Infection intensity was classified followingWHO cutoffs [26]. Geometric and arith-
metic-mean egg counts were calculated for each group before and after treatment. Egg reduc-
tion rates (ERRs) were calculated by the following formula (ERR = (1-(geometricmean at
follow-up/geometricmean at baseline))100). Bootstrap resampling method with 2,000 repli-
cates were used to calculate 95% confidence intervals (CIs) for ERRs. Differences in ERRs were
determined under the assumption that non-overlapping CIs indicate statistical significance.
Cure rates (CRs) were calculated as the percentage of children who became egg-negative after
treatment, being egg-positive at baseline.
Results
Study flow
The study flowcharts are presented in Figs 1 and 2. In the S. haematobium study we screened
268 children/adolescents of which 52 were negative for infection, 23 did not provide any urine
sample, 60 delivered less than 3 urine samples, and 5 were excluded at physical examination
because they did not meet the inclusion criteria. In total 128 participants were enrolled and
randomly assigned to one of the four treatments as follows: 31 subjects receivedmoxidectin, 32
were treated with Synriam plus praziquantel, 33 were administered Synriam and 32 were
treated with praziquantel. Of all participants, 110 were present at the follow up examination
and 18 were lost to follow up (Fig 1).
In the S.mansoni study we screened 388 subjects among whom 25 were negative for a S.
mansoni infection, 158 did not provide 2 stool samples, and 72 did not appear at the treatment
venue. Five subjects were excluded because they did not meet the inclusion criteria.
Participants were randomly assigned to either moxidectin (n = 34), Synriam plus praziquan-
tel (n = 30), Synriam (n = 32) and praziquantel (n = 32). In total we treated 128 subjects and
116 were present at the follow up examination (12 lost to follow up) (Fig 2).
Baseline characteristics
Demographic and clinical baseline characteristics are summarized in Tables 1 and 2. Treatment
groups in the S. haematobium trial were well balanced in terms of age (mean age: 13.5 years,
range: 12–17 years), sex (58.6%male participants), weight (mean weight: 39.4 kg), height
(mean height: 149.2 cm) and baseline infection intensity. The arithmetic and geometricmean
number of S. haematobium eggs per 10 ml was 53.4 and 17.1, respectively. 70% of participants
had light and 30% moderate to heavy infections. Twenty-eight (21.9%) of the 128 treated sub-
jects had a coinfectionwith STH. Microhematuria was detected in 61 (49%) subjects. Eighty-
two (65.6%) of the 128 treated subjects were malaria positive based on thick and thin smears
and 72.6% based on RDT.
Among the participants in the S.mansoni trial, 55.5% were male and the mean age was 12.8
(12–17) years (Table 2). No differences among treatment arms were observed in terms of
SynriamandMoxidectin for Schistosomiasis
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weight (mean weight 35.2 kg), height (139 cm), gender (71 males) except from the Synriam
plus praziquantel treatment arm, in which 73% of participants were males. The arithmetic and
geometricmean S.mansoni infection load was 216.6 and 109.1 epg, respectively. 59 (46.1%) of
adolescents had light infections and 69 (53.9%) moderate to heavy infections. 49 (38.3%) of
participants had a coinfectionwith STH. 101 (78.1%) of the S.mansoni-infected adolescents
were malaria positive according to thick and thin smear and 99 (77.3%) according to the RDT.
Efficacy againstS. haematobium and S.mansoni
We observed a low efficacy for the two novel treatments in the S. haematobium cohort
(Table 3). In more detail, moxidectin and Synriam achieved CRs of 14.8% (95% CI 0.04–0.3)
and 11.1% (95% CI 0.02–0.3), and ERRs of 8.7% (95% CI -0.4–0.6) and 0% (95% CI -0.8–0.6),
respectively. The two treatment arms containing praziquantel (Synriam plus praziquantel and
praziquantel) yielded CRs of 60% (95% CI 0.4–0.8) and 38.5% (95% CI 0.2–0.6) and ERRs of
96% (95% CI 0.8–1.0) and 93.5% (95% CI 0.8–1.0), respectively.
Results of the S.mansoni cohort are reported in Table 4. ERRs were as follows: moxidectin
70.9% (95% CI 0.4–0.9), Synriam 64.9% (95% CI 0.4–0.8), Synriam plus praziquantel 77.6%
(95% CI 0.5–1.1), and praziquantel 87.5% (95% CI 0.8–1.0). The CRs based on Kato-Katz were
12.9% (95% CI 0.03–0.3) for moxidectin, 6.7% (95% CI 0.01–0.2) for Synriam, 27.0% (95% CI
0.1–0.5) for Synriam plus praziquantel, and 27.6% (95% CI 0.1–0.5) for praziquantel. Prazi-
quantel showed a moderate CR of 50.0% in adolescents harboring a low intensity infection.
CRs according to CCA (trace results considered as positive) were 17.9%, 30.4%, 20%, 14.3% for
moxidectin, Synriam plus praziquantel, Synriam, and praziquantel, respectively.
Fig 1. Study flow in theS. haematobium study.
doi:10.1371/journal.pntd.0005008.g001
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Fig 2. Study flow in theS.mansonistudy.
doi:10.1371/journal.pntd.0005008.g002
Table 1. Baseline characteristics of adolescents infectedwithS. haematobium stratifiedby treatmentgroup. The study was carried out in the vil-
lages of Moronou in central Côte d’Ivoire, between May and June 2015.
Moxidectin (N = 31) Synriamplus praziquantel (N = 32) Synriam (N = 33) Praziquantel (N = 32) Total (N = 128)
Age (years) [mean (SD)] 13.8 (0.25) 13.6 (0.2) 13.5 (0.2) 13.3 (0.2) 13.5 (1.1)
Males N (%) 20 (64.5) 19 (59.4) 20 (60.6) 16 (50) 75 (58.6)
Hemoglobin (g/dl) [mean (SD)] 11.9 (0.1) 11.9 (0.2) 11.7 (0.1) 11.8 (0.2) 11.9 (0.1)
Weight (kg) [mean (SD)] 41.0 (1.6) 38.8 (1.3) 38.0 (1.8) 39.9 (1.9) 39.4 (0.8)
Height (cm) [mean (SD)] 150.0 (2.0) 148.8 (1.5) 148.9 (1.9) 148.9 (1.9) 149.2 (0.9)
EPG (AM) 55.0 52.4 53.9 52.1 53.4
EPG (GM) 16.8 16.6 16.9 18.2 17.1
Infection intensity N (%)
Light 22 (71.0) 23 (72.0) 23 (70.0) 22 (69.0) 90 (70.3)
High 9 (29.0) 9 (28.0) 10 (30.0) 10 (31.0) 38 (29.7)
Microhematuria positive N (%) 17 (57.0) 14 (46.0) 16 (59.0) 14 (44.0) 61 (49.0)
STH coinfection N (%) 5 (16.1) 7 (21.9) 9 (27.3) 7 (21.9) 28 (21.9)
MalariaRDT positive N (%) 20 (64.5) 22 (68.7) 26 (78.7) 25 (78.1) 93 (72.6)
Malaria direct smear positive N
(%)
20 (64.5) 22 (68.7) 18 (58.0) 22 (71.0) 82 (65.6)
SD, standard deviation; AM, arithmeticmean; GM, geometric mean, EPG, eggs per gram, RDT, rapid diagnostic test
doi:10.1371/journal.pntd.0005008.t001
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Table 2. Baseline characteristics of adolescents infectedwithS.mansonistratifiedby treatmentgroup. The study was carried out in the villages of
Bigouin and Biakalé in westernCôte d’Ivoire, betweenMay and June 2015.
Moxidectin (N = 34) Synriamplus praziquantel (N = 30) Synriam (N = 32) Praziquantel (N = 32) Total (N = 128)
Age (years) 12.9 (0.2) 12.7 (0.2) 12.8 (0.3) 12.8 (0.3) 12.8 (0.1)
Males N (%) 17 (50.0) 22 (73.3) 15 (46.8) 17 (53.1) 71 (55.5)
Hemoglobin (g/dl) [mean (SD)] 12.2 (0.1) 11.7 (0.2) 11.7 (0.2) 11.8 (0.2) 11.8 (0.1)
Weight (kg) [mean (SD)] 34.4 (1.5) 32.8 (1.5) 39.8 (2.2) 33.97 (1.2) 35.2 (0.8)
Height (cm) [mean (SD)] 138.5 (2.0) 136.2 (2.5) 144.7 (2.1) 137.8 (1.8) 139.3 (1.1)
EPG AM 207.5 249.8 191.7 219.8 216.6
EPGGM 100.9 103.2 99.2 139.9 109.1
Light intensity N (%) 17 (50) 13 (43.3) 15 (46.8) 14 (43.8) 59 (46.1)
Moderate intensity N (%) 13 (38.2) 11 (36.7) 13 (40.6) 12 (37.5) 49 (38.3)
High intensity N (%) 4 (11.8) 6 (20.0) 4 (12.5) 6 (18.7) 20 (15.6)
CCA N (%) 29 (90.6) 27 (90.0) 26 (86.7) 29 (90.0) 111 (89.5)
Trace N (%) 2 (6.3) 4 (13.3) 4 (6.7) 0 (0) 8 (6.5)
Low intensity N (%) 5 (15.6) 2 (6.7) 4 (13.3) 3 (3.4) 14 (11.3)
High intensity N (%) 22 (68.8) 21 (70) 20 (66.7) 26 (81.3) 89 (71.8)
STH coinfection N (%) 12 (35.3) 16 (53.3) 13 (40.6) 8 (25.0) 49 (38.3)
MalariaRDT positive N (%) 24 (70.6) 24 (80) 26 (81.2) 25 (78.1) 99 (77.3)
Malaria direct smear positive N
(%)
28 (82.3) 22 (73.3) 24 (75) 27 (84.4) 101 (78.1)
SD, standard deviation; AM, arithmeticmean; GM, geometric mean, EPG, eggs per gram, RDT, rapid diagnostic test
doi:10.1371/journal.pntd.0005008.t002
Table 3. Effect ofmoxidectin, Synriam,Synriamplus praziquantel and praziquantel againstS. haematobium andmalaria co-infections. The study
was carried out in the village of Moronou in central Côte d’Ivoire, betweenMay and June 2015.
Moxidectin (N = 27) Synriamplus Praziquantel
(N = 30)
Synriam (N = 27) Praziquantel (N = 26)
S. haematobium infection
Children cured (%) (CI) 4 (14.8) (0.04–0.3) 18 (60) (0.4–0.8) 3 (11.1) (0.02–
0.3)
10 (38.5) (0.2–0.6)
Children cured with high infection intensity (%) 0/8 (0) 3/9 (33.3) 0/8 (0) 2/7 (28.6)
Children cured with low infection intensity (%) 4/19 (21.1) 15/21 (71.4) 3/19 (15.8) 8/19 (42.1)
EPG before treatmentAM 56.3 54 52.7 47
EPG after treatmentAM 117.6 2.8 83.8 2.07
EPG before treatmentGM 17.2 16 16.1 15.2
EPG after treatmentGM 15.7 0.6 17.7 0.98
Egg reduction rate (%) (95%CI) 8.7 (-0.4–0.6) 96 (0.8–1.0) 0 (-0.8–0.6) 93.5 (0.8–1.0)
Microhematuria positive before treatmentN (%) 16 (61.5) 13 (44.8) 14 (53.8) 12 (46.2)
Microhematuria negative after treatmentN (%) 8 (29.6) 19 (63.3) 9 (33.3) 15 (57.7)
Plasmodium falciparum infection
Number RDT positive before treatment (%) 18 (66.7) 20 (66.7) 21 (77.8) 21 (80.7)
Number children negative based on RDT (%) 10/18 (55.5) 20/20 (100.0) 20/21 (95.0) 14/21 (66.6)
No. malaria direct smear positive before treatment
(%)
18 (66.7) 20 (66.7) 17 (63.0) 19 (73.1)
No. children negative based on malaria smear (%) 10/18 (55.5) 20/20 (100.0) 17/17 (100.0) 12/19 (63.2)
CI, confidence interval; AM, arithmeticmean; GM, geometricmean, EPG, eggs per gram, RDT, rapid diagnostic test
doi:10.1371/journal.pntd.0005008.t003
SynriamandMoxidectin for Schistosomiasis
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Efficacy against co-infections
In the S. haematobium cohort all subjects in both Synriam treatment groups were cured from
malaria infection according to direct smear technique, 5% (1/21) remained positive according
to RDT. At follow up 55.5% of subjects in the moxidectin group were Plasmodium spp. nega-
tive based on both techniques. In the praziquantel treatment group 66.6% and 63.2% of partici-
pants were negative according to RDT and direct smear, respectively.
In the S.mansoni cohort overall 50% of subjects were Plasmodium spp. negative at follow
up. CR in the groups treated with Synriam (praziquantel plus Synriam, Synriam respectively)
were 80% and 95.8%.
In both cohorts none of the treatments showed any efficacy against STH infections (data
not shown).
Tolerability
At clinical examination all 128 subjects in the S. haematobium cohort reported symptoms. The
number of adverse events stratified by treatment arm and evaluation time point are summa-
rized in Table 5. Overall, recorded clinical symptoms decreased from 100% prior to treatment
to 48% (3 hours post-treatment) and 21% (72 hours post-treatment). Three days after the last
treatment administered, none of the participants reported any adverse events. The highest
number of mild adverse events 3 hours post-treatment were recorded in the praziquantel treat-
ment group (58%) and the lowest number in the Synriam plus praziquantel treatment group
(41%). The most commonly observed adverse events were stomach ache (30%) and headache
(19%) (S1 Table).
Table 4. Effect ofmoxidectin, Synriam,Synriamplus praziquantel and praziquantel againstS.mansoni andmalaria co-infections. The study was
carried out in the villages of Bigouin and Biakalé in westernCôte d’Ivoire, betweenMay and June 2015.
Moxidectin (N = 31) Synriamplus Praziquantel (N = 26) Synriam (N = 30) Praziquantel (N = 29)
S.mansoni infection
Children cured (%) (95%CI) 4 (12.9) (0.03–0.3) 7 (27.0) (0.1–0.5) 2 (6.7) (0.01–0.2) 8 (27.6) (0.1–0.5)
Children cured with high infection intensity (%) 0/3 (0) 2/6 (33.3) 0/4 (0) 1/5 (20.0)
Children cured with moderate infection intensity
(%)
2/13 (15.4) 2/9 (22.2) 0/13 (0) 1/12 (8.3)
Children cured with low infection intensity (%) 2/15 (13.3) 3/11 (27.3) 2/13 (15.4) 6/12 (50.0)
EPG before treatmentAM 216.9 272.7 201.6 221.6
EPG after treatmentAM 159.3 176.3 101 121.6
EPG before treatmentGM 106.7 108.4 107 143.6
EPG after treatmentGM 33.5 24.3 37.4 17.9
Egg reduction rate (%) (95%CI) 70.9 (0.4–0.9) 77.6 (0.5–1.1) 64.9 (0.4–0.8) 87.5 (0.8–1)
CCA positive (tr+) before treatmentN (%) 28 (93.3) 23 (88.5) 25 (89.3) 28 (96.5)
CCA positive (tr-) before treatmentN (%) 26 (86.6) 20 (76.9) 23 (82.0) 28 (96.5)
CCA negative (tr+) after treatmentN (%) 5 (17.9) 7 (30.4) 5 (20.0) 4 (14.3)
CCA negative (tr-) after treatmentN (%) 7 (27.0) 8 (40.0) 5 (21.7) 7 (25.0)
Plasmodium falciparum infection
No. RDT positive before treatment (%) 22 (71.0) 20 (77.0) 24 (80.0) 23 (79.0)
No. children negative based on RDT (%) 1 (4.5) 16 (80.0) 23 (95.8) 5 (21.7)
CI, confidence interval; AM, arithmeticmean; GM, geometricmean, EPG, eggs per gram; tr+, trace considered as positive; tr-, trace considered as negative;
RDT, rapid diagnostic test
doi:10.1371/journal.pntd.0005008.t004
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In the S.mansoni cohort 95 subjects reported symptoms (74%) at clinical examination
(Table 6). Overall, 51% of participants had mild symptoms at the first evaluation time point,
ranging from 44% in the moxidectin group to 57% in the praziquantel treatment group. 15% of
participants had symptoms 72 hours post-treatment and 3 days after the last treatment dose
none of the participants reported symptoms.
All events reported were mild, the most common symptoms were stomach ache (29%) and
headache (10%). Only one subject had a moderate adverse event, namely eye swelling, which
was resolved following antihistamine treatment. S1 Table and S2 Table summarize clinical
symptoms stratified by treatment arm and assessment time for the S. haematobium and S.
mansoni studies.
Discussion
To our knowledge we have for the first time assessed the efficacy of Synriam and moxidectin
against S.mansoni and S. haematobium infections. It is crucial to develop alternatives to prazi-
quantel for the treatment of schistosomiasis, but lately no new drug candidates entered the
Table 5. Number of adolescents with clinical symptomsobserved prior to treatmentand adverse events in theS. haematobium study among the
four different treatment arms, assessed at different time points. The study was carried out in the villages of Moronou, Bigouin and Biakalé in central
Côte d’Ivoire, betweenMay and June 2015.
Evaluation time points Moxidectin (N = 31) Synriamplus praziquantel
(N = 32)
Synriam (N = 33) Praziquantel (N = 32) Overall (n = 128)
Clinical symptoms before
treatment
31 (100.0) 32 (100.0) 33 (100.0) 32 (100.0) 128 (100.0)
3 hours after first treatment 14 (45.0) 13 (41.0) 17 (52.0) 18 (58.0) 62 (48.4)
24 hours after first treatment 9 (29.0) 9 (28.0) 4 (12.0) 6 (19.0) 28 (21.8)
72 hours after first treatment 7 (23.0) 9 (28.0) 6 (18.0) 5 (16.0) 27 (21.1)
3 hours after second treatment NA 3 (9.0) 1 (3.0) NA 4/65 (6.2)
24 hours after second treatment NA 1 (3.0) 0 (0) NA 1/65 (1.5)
72 hours after second treatment NA 0 (0) 0 (0) NA 0/65 (0)
3 hours after third treatment NA 1 (3.0) 0 (0) NA 1/65 (1.5)
24 hours after third treatment NA 1 (3.0) 0 (0) NA 1/65 (1.5)
72 hours after third treatment NA 0 (0) 0 (0) NA 0/65 (0)
doi:10.1371/journal.pntd.0005008.t005
Table 6. Number of adolescents with clinical symptomsobserved prior to treatmentand adverse events in theS.mansonistudy among the four
different treatment arms, assessed at different time points. The study was carried out in the villages of Moronou, Bigouin and Biakalé in central Côte
d’Ivoire, between May and June 2015.
Evaluation time points Moxidectin (N = 34) Synriamplus praziquantel
(N = 30)
Synriam (N = 32) Praziquantel (N = 32) Overall (N = 128)
Clinical symptoms before
treatment
26 (76.0) 22 (73.0) 26 (81.0) 21 (65.0) 95 (74.2)
3 hours after first treatment 15 (44.0) 17 (57.0) 16 (50.0) 17 (53.0) 65 (50.7)
24 hours after first treatment 10 (29.0) 9 (30.0) 2 (6.0) 6 (19.0) 27 (21.1)
72 hours after first treatment 7 (21.0) 6 (20.0) 3 (9.0) 3 (9.0) 19 (14.8)
3 hours after second treatment NA 1 (3.0) 0 (0) NA 1/62 (1.6)
24 hours after second treatment NA 1 (3.0) 0 (0) NA 1/62 (1.6)
72 hours after second treatment NA 1 (3.0) 0 (0) NA 1/62 (1.6)
3 hours after third treatment NA 1 (3.0) 0 (0) NA 1/62 (1.6)
24 hours after third treatment NA 1 (3.0) 1 (3.0) NA 2/62 (3.2)
72 hours after third treatment NA 0 (0) 0 (0) NA 0/62 (0)
doi:10.1371/journal.pntd.0005008.t006
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drug discovery and development pipeline for this NTD [6]. Repurposing of existing drugs with
different treatment indications as in the present exploratory trial, might be the way forward in
order to find alternatives to praziquantel in a fast and cost-effectivemanner [27].
Based on promising findings in preclinical or clinical studies, two drugs were selected for
our study, Synriam a new generation antimalarial drug and moxidectin, which will soon be
marketed for the treatment of onchocerciasis [19, 28]. Disappointingly, we observed low effi-
cacy of moxidectin and Synriam in terms of ERR and CR against S. haematobium though infec-
tion intensities in study participants were low. The highest CR and ERR (60% and 96%) were
observed for Synriam plus praziquantel treated participants. Though the drugs were not
administered simultaneously since possible drug interactions have not been studied to date,
both treatments might have positively influenced each other. It could be hypothesized that the
damage caused by praziquantel on S. haematobium was exacerbated by treatment with Syn-
riam, which resulted in a slightly better efficacywhen the two drugs were administered
together. However, our study was not powered to detect statistical differences among treatment
arms, hence studies with larger samples sizes would be necessary to confirm this finding.
Interestingly, against S.mansoni bothmoxidectin and Synriam alone performed better than
against S. haematobium with higher ERRs observedbut not CRs. The better efficacy of moxi-
dectin and Synriam against S.mansoni in terms of ERRs cannot be explained at the moment.
Fluctuations in egg counts might also play a role. However, the ERR observed for moxidectin
in the present study is in line with previous results on S.mansoni [18]. In contrast with our
findings in S. haematobium treated adolescents, in the S.mansoni study no increased efficacy
was observedwith Synriam plus praziquantel over praziquantel alone.
The findings on praziquantel observed in the two trials warrant further discussion. First,
observedERRs of praziquantel were similar in both cohorts (87.5–93.5%) and in accordance
with previous findings [5, 29]. However, strikingly, praziquantel showed low CRs in partici-
pants infected with S. haematobium (38.4%) and S.mansoni (27.6%). These CRs are notably
lower (except for one of our own studies in a nearby setting [5]) than in previous reports,
which have documentedCRs (for a single dose of praziquantel (40 mg/kg)) ranging from 51 to
100% against S.mansoni and S. haematobium. Our findings underline the great variability of
CRs linked to praziquantel treatment [30]. As discussed elsewhere [31,32] the low CRs of prazi-
quantel in the S.mansoni cohort might be due to the fact that half of participants suffered from
moderate/heavy infection intensity. Praziquantel revealed a higher CR of 50% in adolescents
with low intensity S.mansoni infections. Similarly, a higher CR (42%) was observed in partici-
pants with a low S. haematobium infection intensity.
Many clinical trials have been conducted using artemether and artesunate alone and in
combination with praziquantel [33]. The moderate efficacies against S.mansoni and S. haema-
tobium observedwith the antimalarial Synriam in our trial are in line with previous studies
using peroxidic drugs as monotherapy against chronic schistosome infections [34, 35]. For
example, a recent meta-analysis determined that artesunate has a low CR against chronic S.
haematobium infection (25%) [34, 36]. This finding is not surprising since artemisinin deriva-
tives mainly act on juvenile schistomes [8]. We had therefore initially planned a second follow
up at 50 (S.mansoni) and 80 days (S. haematobium) after treatment, to assess the efficacy of
Synriam against prepatent infections. However, this additional surveywas not conducted, due
to the low efficacy observed at the first follow up, which made it impossible to assess activity
against juvenile schistosome infections. Follow up studies could be planned to assess the pro-
phylactic effect of Synriam and Synriam plus praziquantel against infections with S.mansoni
and S. haematobium.
In the S. haematobium cohort we used both filtration and assessment of microhaematuria.
Our data confirm [37] that the evaluation of microhematuria for the diagnosis of S.
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haematobium has a lower sensitivity compared to the filtrationmethod. However, urine filtra-
tion was performed on three samples while microhaematuria was investigated on only one.
Furthermore, the majority of participants in our study had low S. haematobium intensity
infections.
In both settings we examined Plasmodium infections: based on RDT in both cohorts
infected adolescents treated with Synriam were all cured with the exception of four patients
(CRs 80–100%). CRs with the thin and thick smears were slightly lower. To date few studies
have been conducted with Synriam against Plasmodium infections: two on the African and
Asian continents reported CRs of 90–99% 28 days after treatment, a second follow up was per-
formed 42 days after the last dose of drug and 100% of participants had no gametocytes [38].
The rate of reinfection was lower than 0.5% at 28 days [38]. Similar results were found in
another study comparing artemether plus lumefantrine and Synriam, with all patients being
cured 28 days post-treatment [39]. The moderate CRs observed in the praziquantel and moxi-
dectin treated groups in the S. haematobium setting cannot fully be elucidated. Spontaneous
clearance might have occurred, however we also cannot rule out self-treatments.
Interestingly, in both trials a higher number of clinical symptoms was observedbefore treat-
ment compared to post-treatment. For example, before treatment 41% (S. haematobium
cohort) and 54% (S.mansoni cohort) participants reported headache, whereas 3 hours after
treatment only 19% and 10% reported this symptom in the two cohorts, respectively. A similar
finding was observed for stomach ache, which rapidly improved after treatment. These results
are contradictory to most studies, which observe a worsening of gastrointestinal symptoms fol-
lowing treatment with praziquantel most likely due to dying worms [29]. We cannot fully
explain our findings, however it might be worth highlighting that the number of participants
complaining about symptoms prior to treatment was very high, higher than in previous studies,
which makes it difficult to present a clear picture on the occurrence of adverse events. In addi-
tion, it is not possible to distinguish between an actual improvement in their conditions (which
however seems to have occurred too fast) or a perceived improvement, driven by participants'
expectations or other factors.
In conclusion, the two drugs tested (moxidectin and Synriam) showed low efficacy against
S. haematobium infections.We therefore do not expect a significant ancillary benefit when
these two drugs are used for the treatment of onchocerciasis and malaria in settings co-
endemic for S. haematobium. We observed a better performance of both drugs in terms of ERR
against S.mansoni infection. Studies with larger sample size are needed to confirm our finding
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